U.S. Stock News

NasdaqGM:BCBP
NasdaqGM:BCBPBanks

BCB Bancorp (BCBP) Cost To Income Spike To 120% Tests Profitability Recovery Narrative

BCB Bancorp (BCBP) just posted its FY 2025 numbers with fourth quarter total revenue of US$14.0 million and a basic EPS loss of US$0.73, while trailing twelve month figures show total revenue of US$59.6 million and a basic EPS loss of US$0.84. Over recent periods, total revenue has shifted from US$23.3 million in Q3 2024 to US$19.0 million in Q4 2024 and then to US$14.0 million in Q4 2025, with quarterly EPS moving from US$0.36 to US$0.16 and then to a loss of US$0.73 over the same points in...
NasdaqGS:COLB
NasdaqGS:COLBBanks

Columbia Banking System Unites CEO And Chair Roles As Oversight Focus Grows

Columbia Banking System (NasdaqGS:COLB) has appointed its President and CEO, Clint Stein, as Chair of the Board. This board leadership change consolidates executive and board roles under Stein. The move follows a period that included a major acquisition and recent strong quarterly performance. For investors, the combination of CEO and Chair at Columbia Banking System comes at a time when the stock trades at $29.44 and has returned 11.5% over the past year and 46.4% over the past 5 years...
NYSE:AFG
NYSE:AFGInsurance

Is American Financial Group (AFG) Attractive After Recent Insurance Sector Interest And Mixed Returns?

If you are wondering whether American Financial Group is priced fairly today, you are not alone, especially with the stock often viewed through the lens of long term value. The share price closed at US$130.27, with returns of 1.9% over the last 7 days, a 3.4% decline over the last 30 days, 3.4% decline year to date, 0.8% over 1 year, 17.1% over 3 years, and 116.4% over 5 years. Recent news flow around American Financial Group has centred on ongoing interest in the US insurance space and how...
NYSE:CUBI
NYSE:CUBIBanks

Customers Bancorp (CUBI) Is Up 6.0% After Raising 2026 NII Outlook And Payments Volumes Soar

In late January 2026, Customers Bancorp reported fourth-quarter 2025 results showing higher net interest income of US$204.43 million and net income of US$74.49 million, alongside full-year 2025 gains and slightly lower quarterly net charge-offs of US$14 million. The bank also issued 2026 net interest income guidance of US$800 million to US$830 million and highlighted leadership changes and payments growth, including record cubiX volumes above US$2 trillion and new executive appointments...
NYSE:TGT
NYSE:TGTConsumer Retailing

Is Target (TGT) Pricing Reflect Its Value After Recent Share Price Weakness

If you are wondering whether Target's current share price reflects its underlying value, this article walks through the numbers in a clear and practical way. Target's stock last closed at US$105.47, with returns of 4.9% over the past month, a 20.1% decline over the past year, and a 33.8% decline over three years. This performance may change how investors think about its risk and return profile. Recent news around Target has focused on its position in US consumer retail and how it is...
NasdaqGS:OSIS
NasdaqGS:OSISElectronic

Is It Too Late To Consider OSI Systems (OSIS) After Recent Share Price Pullback?

If you are wondering whether OSI Systems at around US$250 per share is offering fair value or not, you are in the right place to unpack what the current price might be implying. The stock has seen a 9% decline over the last 7 days and a 2.1% decline over the last 30 days and year to date, while its 1 year return sits at 27.3% and its 3 year and 5 year returns are 158.7% and 167.8% respectively. These moves have come alongside ongoing attention on OSI Systems as a technology name. Investors...
NYSE:MOG.A
NYSE:MOG.AAerospace & Defense

Is It Too Late To Consider Moog (MOG.A) After A 69% One-Year Surge?

If you are wondering whether Moog's current share price still makes sense for new money, or if most of the easy gains are already on the table, you are in the right place. Moog's share price recently closed at US$305.35, with returns of 4.7% over the last week, 22.2% over the last month, 22.2% year to date, 69.1% over the last year, and a very large gain over five years of around 3x. Recent attention around Moog has centred on its position in capital goods and investor interest in companies...
NasdaqGS:IONS
NasdaqGS:IONSBiotechs

Barclays’ Supportive View on Ionis’s RNA Pipeline and Partnerships Might Change The Case For Investing In Ionis Pharmaceuticals (IONS)

In late January 2026, Barclays analyst Eliana Merle initiated coverage on Ionis Pharmaceuticals with a positive rating, spotlighting its RNA-targeted therapy pipeline and extensive collaborations with large biopharma partners. This coverage underscored how Ionis’s late-stage candidates like Olezarsen and Donidalorsen, alongside alliances with firms such as Biogen and AstraZeneca, are shaping investor interest in the company’s future prospects. Next, we’ll examine how this supportive analyst...
NasdaqGS:JOYY
NasdaqGS:JOYYInteractive Media and Services

Is It Time To Reassess JOYY (JOYY) After Strong Multi Year Share Price Gains

If you are wondering whether JOYY's current share price reflects its underlying worth, this article walks through what the numbers are saying about the stock's value today. JOYY's share price closed at US$64.35, with a 7.3% decline over the last 7 days, a 0.6% decline over 30 days, a 0.6% decline year to date, a 59.6% return over 1 year, and a 102.4% return over 3 years, while the 5 year return stands at a 31.2% decline. Recent coverage around JOYY has focused on its position in the online...
NasdaqGS:HOLX
NasdaqGS:HOLXMedical Equipment

Assessing Hologic (HOLX) Valuation After Steady Returns And Modest Undervaluation Estimate

Hologic (HOLX) is drawing investor attention after recent trading, with shares last closing at US$74.93 and modest moves over the past month and past 3 months prompting a closer look at fundamentals. See our latest analysis for Hologic. Looking beyond the past few weeks, Hologic’s share price has been relatively steady, with modest positive share price returns over the past quarter and year to date. However, the 1 year total shareholder return of 3.87% contrasts with negative 3 and 5 year...
NYSE:EW
NYSE:EWMedical Equipment

Has Edwards Lifesciences (EW) Price Slide Created A Fair Value Opportunity?

If you are wondering whether Edwards Lifesciences is offering good value at its current share price, this article will walk you through what the numbers are really saying. The stock most recently closed at US$81.36, with a 7 day return of a 2.7% decline, a 30 day return of a 4.7% decline, and a 12.3% gain over the last year, which may have some investors reassessing both risk and upside. Recent news flow around Edwards Lifesciences has focused on its position in medical devices and investor...
NasdaqGS:ALMS
NasdaqGS:ALMSPharmaceuticals

Assessing Alumis (ALMS) Valuation After Successful Phase III Results For Envudeucitinib

Alumis (ALMS) is back in focus after reporting successful Phase III results for its TYK2 inhibitor, envudeucitinib, in moderate to severe plaque psoriasis. This clinical milestone has prompted fresh attention from Wall Street research desks. See our latest analysis for Alumis. Despite a one-day share price return of negative 8.68% leaving Alumis at US$24.51, the 30-day and year-to-date share price returns of 173.70% and a 1-year total shareholder return of 227.67% suggest momentum has been...
NYSE:AON
NYSE:AONInsurance

Aon Expands Climate Platform With €260m Emerging Markets Transition Fund

Aon (NYSE:AON) has launched a €260m emerging markets climate transition fund in partnership with Irish Life. The new fund brings Aon Ireland’s climate related investment strategies to over €1b. The move highlights growing client demand for climate focused and ESG aligned investment solutions. Aon, trading at $349.64, sits in a space where investors often watch both its advisory role and its own capital allocation choices. Over 5 years, the stock is up 62.6%, with a 14.0% return over 3...